Zhang A, Fan L, Liu Q, Zuo X, Zhu J
Cancer Innov. 2025; 4(2):e70003.
PMID: 40061827
PMC: 11885950.
DOI: 10.1002/cai2.70003.
Barillaro A, Caroprese M, Feoli C, Chioccola E, Goodyear C, Oliviero C
Explor Target Antitumor Ther. 2025; 6:1002290.
PMID: 40061141
PMC: 11886383.
DOI: 10.37349/etat.2025.1002290.
Conte M, Carofiglio M, Vander Pol R, Wood A, Hernandez N, Joubert A
ACS Appl Mater Interfaces. 2025; 17(8):11873-11887.
PMID: 39960802
PMC: 11873934.
DOI: 10.1021/acsami.4c21975.
Rafiq Z, Kang M, Barsoumian H, Manzar G, Hu Y, Leuschner C
J Exp Clin Cancer Res. 2025; 44(1):31.
PMID: 39881333
PMC: 11781074.
DOI: 10.1186/s13046-025-03281-2.
Ostoich P
Int J Mol Sci. 2025; 26(1.
PMID: 39796112
PMC: 11719969.
DOI: 10.3390/ijms26010257.
Genomic predictors of radiation response: recent progress towards personalized radiotherapy for brain metastases.
Harary P, Rajaram S, Chen M, Hori Y, Park D, Chang S
Cell Death Discov. 2024; 10(1):501.
PMID: 39695143
PMC: 11655559.
DOI: 10.1038/s41420-024-02270-2.
The Impact of Synchrotron Microbeam Radiation Therapy Combined With Broad Beam in a Preclinical Breast Cancer Model.
Engels E, Forrester H, Klein M, Bell C, Balderstone I, Brunt K
Adv Radiat Oncol. 2024; 10(1):101680.
PMID: 39687472
PMC: 11647509.
DOI: 10.1016/j.adro.2024.101680.
Comparing the outcomes of MR-based versus CT-based tumor delineation in locally advanced non-small cell lung cancer treated with hypo-fractionated radiotherapy and concurrent chemotherapy.
Zhang P, Ding S, Peng K, He H, Wang D, Zhou R
Transl Lung Cancer Res. 2024; 13(11):2890-2902.
PMID: 39670014
PMC: 11632429.
DOI: 10.21037/tlcr-24-341.
Pulsed electric field ablation as a candidate to enhance the anti-tumor immune response to immune checkpoint inhibitors.
Arciga B, Walters D, Kimchi E, Staveley-OCarroll K, Li G, Teixeiro E
Cancer Lett. 2024; 609:217361.
PMID: 39608443
PMC: 11625606.
DOI: 10.1016/j.canlet.2024.217361.
Multifunctional nanocomposites utilizing ruthenium (II) complex/manganese (IV) dioxide nanoparticle for synergistic reinforcing radioimmunotherapy.
Peng J, Quan D, Yang G, Wei L, Yang Z, Dong Z
J Nanobiotechnology. 2024; 22(1):735.
PMID: 39593029
PMC: 11600833.
DOI: 10.1186/s12951-024-03013-2.
Current views on mechanisms of the FLASH effect in cancer radiotherapy.
Ma Y, Zhang W, Zhao Z, Lv J, Chen J, Yan X
Natl Sci Rev. 2024; 11(10):nwae350.
PMID: 39479528
PMC: 11523052.
DOI: 10.1093/nsr/nwae350.
13-year survival oligometastatic Merkel cell carcinoma: a case report.
Trampetti I, Faivre J, Geoffrois L, Gehin W, Renard S
J Med Case Rep. 2024; 18(1):455.
PMID: 39289742
PMC: 11409691.
DOI: 10.1186/s13256-024-04750-6.
High-dose radiation-induced immunogenic cell death of bladder cancer cells leads to dendritic cell activation.
Zeng X, Luo D, Zhang S, Cui Z, Wang Y, Chen J
PLoS One. 2024; 19(9):e0307024.
PMID: 39231199
PMC: 11373825.
DOI: 10.1371/journal.pone.0307024.
Immunotherapy Plus Chemoradiation Improves Overall Survival in Stage IV Esophageal Cancer: A Cohort Study.
Amin S, Lin C
Gastro Hep Adv. 2024; 3(3):302-310.
PMID: 39131143
PMC: 11307788.
DOI: 10.1016/j.gastha.2023.12.004.
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer.
Eapen R, Williams S, MacDonald S, Keam S, Lawrentschuk N, Au L
Nat Rev Urol. 2024; 21(11):676-686.
PMID: 39112733
DOI: 10.1038/s41585-024-00913-8.
Shifting cold to hot tumors by nanoparticle-loaded drugs and products.
Ahmad I, Atiyah Altameemi K, Hani M, Ali A, Shareef H, Hassan Z
Clin Transl Oncol. 2024; 27(1):42-69.
PMID: 38922537
DOI: 10.1007/s12094-024-03577-3.
A DNA tetrahedron-based nanosuit for efficient delivery of amifostine and multi-organ radioprotection.
Yang Y, Yang J, Zhu J, Chen X, Zhou L, Ma W
Bioact Mater. 2024; 39:191-205.
PMID: 38808157
PMC: 11131065.
DOI: 10.1016/j.bioactmat.2024.05.017.
Non-targeted effects of radiation therapy for glioblastoma.
Lerouge L, Ruch A, Pierson J, Thomas N, Barberi-Heyob M
Heliyon. 2024; 10(10):e30813.
PMID: 38778925
PMC: 11109805.
DOI: 10.1016/j.heliyon.2024.e30813.
The efficacy and safety of stereotactic body radiotherapy combined with systematic therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis.
Zhang S, Xiong X, Xie N, Zheng W, Li Y, Lin T
MedComm (2020). 2024; 5(5):e544.
PMID: 38660686
PMC: 11042534.
DOI: 10.1002/mco2.544.
Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases.
Liang X, Jiang Y, Yao W, Deng Y, Yang S, Liu Q
Transl Cancer Res. 2024; 13(3):1508-1518.
PMID: 38617508
PMC: 11009807.
DOI: 10.21037/tcr-23-1333.